Annales pharmaceutiques francaises最新文献

{"title":"Neuroprotective Potential of Green-Synthesized Silver Nanoparticles from Psidium guajava in a Scopolamine-Induced Rat Model of Alzheimer's Disease.","authors":"Adesh Tagad, Sunil T Galatage, Nanjappaiah Hankuntimath, Shivakumar Hugar, Shrinivas R Raikar, Virupanagouda P Patil, S Manjappa Arehalli","doi":"10.1016/j.pharma.2025.10.006","DOIUrl":"https://doi.org/10.1016/j.pharma.2025.10.006","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a chronic neurodegenerative condition marked by progressive memory decline and cognitive dysfunction, and oxidative stress, with no definitive cure currently available. The present study aimed to develop a plant-based nanotherapeutic approach for AD by synthesizing silver nanoparticles (AgNPs) using the ethanolic leaf extract of Psidium guajava (PG) via a green synthesis method. Formation of PG-AgNPs was confirmed by a characteristic surface plasmon resonance (SPR) peak observed in UV-Visible spectroscopy and a visible colour change to dark brown. The synthesized nanoparticles exhibited a mean particle size of 107 ± 4 nm, a polydispersity index (PDI) of 0.364 ± 0.08, and a zeta potential of -30.7 ± 2.3 mV, indicating good colloidal stability. Energy-dispersive X-ray diffraction (E-XRD) confirmed the crystalline nature and elemental composition of silver. In a scopolamine-induced rat model of AD, treatment with PG-AgNPs significantly improved cognitive performance. Rats treated with PG-AgNPs showed a statistically significant increase (p < 0.001) in spontaneous alternation behaviour, prolonged step-through latency in the passive avoidance test (p < 0.001), and a significant reduction in escape latency time in the Morris Water Maze test (p < 0.001) compared to the disease control group. Biochemical analyses revealed that PG-AgNPs significantly reduced lipid peroxidation (LPO) levels (p < 0.001) and significantly increased catalase (CAT) activity (p < 0.001), indicating strong antioxidant potential. In conclusion, Psidium guajava leaf extract and its green-synthesized silver nanoparticles demonstrated statistically significant neuroprotective, antioxidant, and cognitive-enhancing effects, supporting their potential as a novel therapeutic strategy for the treatment of Alzheimer's disease. Further research is needed to explore and conform their clinical applicability.</p>","PeriodicalId":521031,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Eco-prescription, a new major skill for healthcare professionals].","authors":"Frédéric Bounoure, Salomé Dupray, Julien Wils, Sébastien Taillemite, Matthias Brunn, Charlotte Siefridt, Noémie Le Clech, Mathilde Réveillon Istin, Mohamed Skiba, Céline Bougle, Malika Skiba","doi":"10.1016/j.pharma.2025.10.003","DOIUrl":"https://doi.org/10.1016/j.pharma.2025.10.003","url":null,"abstract":"<p><p>Healthcare-related carbon emissions account for about 8% of national emissions. Drugs are the primary source of emissions, contributing 9.1 Mt of CO₂ per year. The objective of this work is to better define the eco-prescription of medicines and the means of implementation to favor therapeutic strategies that are more environmentally virtuous while maintaining the quality of care.The most relevant recommendations were identified by a study of the current recommendations coupled with a bibliographical analysis. It was supplemented by an analysis of the Ecovamed® database on the carbon footprint of medicines. This study covered nine classes of common drugs. The functional unit used was the standardized Daily Defined Dose (DDD) on a monthly package. Five principles of eco-prescription have been proposed: Give preference to dry oral forms (greenhouse gas emissions divided by 2 to 130), Avoid prescribing pressurized inhalers (emissions divided by 10 to 20 when using powder inhalers), Give preference within the same therapeutic class to drugs with the lowest daily doses of active ingredient (reduction of 30% vs. the average of therapeutic class), give preference to drugs combining several active substances in the same dose (reduction of 29% vs. the 2 drugs ) and Give preference to a dosage schedule with minimum administered doses (reduction of 37%).Their use by healthcare professionals is simple, with a significant effect and constant cost. However, these principles must be part of a global approach focused on the proper use and relevance of care. Eco-prescription represents a major change in our pharmaceutical and medical practices.</p>","PeriodicalId":521031,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145277072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paleoproteomics reveals chromoblastomycosis as possible cause of King of France Louis XIV’s death (1715).","authors":"Philippe Charlier, Victoria Pelzer, Anaïs Augias, Lotfi Slimani, Catherine Chaussain, Joël Poupon, Speranta-Maria Popescu, Mélodie Kielbasa, Djillali Annane, Jean Armengaud","doi":"10.1016/j.pharma.2025.10.005","DOIUrl":"https://doi.org/10.1016/j.pharma.2025.10.005","url":null,"abstract":"","PeriodicalId":521031,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145277112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensuring data integrity in the pharmaceutical lifecycle: Challenges, principles, and global implications.","authors":"Monali Rushi Dakhole, Kalyani Ramprasad Thombre, Krishna Radheshyam Gupta, Milind Janrao Umekar","doi":"10.1016/j.pharma.2025.10.002","DOIUrl":"10.1016/j.pharma.2025.10.002","url":null,"abstract":"<p><p>Data integrity is a cornerstone of the pharmaceutical sector's capacity to provide safe, efficacious, and high-quality medicinal products. It guarantees that data remains accurate, consistent, comprehensive, and dependable across the entire product lifecycle, encompassing research, clinical development, manufacturing, regulatory submissions, and post-marketing surveillance. This discourse explains the significance of data integrity in maintaining regulatory adherence, safeguarding patient welfare, and upholding quality benchmarks. It delves into the principles of ALCOA and ALCOA+, underscores the critical nature of Good Documentation Practices (GDP), and identifies prevalent threats such as data falsification, inadequate documentation, and insufficient system controls. Empirical case studies exemplify the grave repercussions of data breaches, alongside the advantages of robust data governance frameworks. The review further accentuates how compromised data can culminate in hazardous products and erosion of public confidence. Ultimately, it proposes methodologies for bolstering data integrity, fostering a culture of transparency, and ensuring regulatory conformity to facilitate consistent and reliable pharmaceutical operations globally.</p>","PeriodicalId":521031,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CHARACTERIZATION OF THROMBOEMBOLIC EVENTS AFTER RECOMBINANT COAGULATION FACTOR VIIa (rFVIIa - NOVOSEVEN®) USE IN CARDIAC SURGERY: A DESCRIPTIVE PILOT STUDY.","authors":"Delphine Boden, Camille Bouchand, Charles-Henri David, Jean-Christophe Rigal, Marion Bonsergent","doi":"10.1016/j.pharma.2025.10.004","DOIUrl":"https://doi.org/10.1016/j.pharma.2025.10.004","url":null,"abstract":"<p><strong>Objectives: </strong>Cardiac surgery carries a high risk of bleeding. In the event of massive bleeding, the administration of rFVIIa may be necessary. However, due to the thromboembolic risk, the use of this factor is only recommended for severe bleeding that does not respond to standard treatments. Our aim was to describe the use of rFVIIa in bleeding situations in cardiac surgery and the thromboembolic events after administration.</p><p><strong>Methods: </strong>This is a monocentric observational study including patients who received rFVIIa from January 2019 to December 2021 for the treatment of massive bleeding associated with cardiac surgery. Data collected included population characteristics, surgery, bleeding management, rFVIIa prescription and incidence of postoperative thromboembolic events.</p><p><strong>Results: </strong>A total of 67 patients were included. Most of the operations were for aortic dissection (46%) and valve replacement (33%), and 54% of the cases were urgent procedures. Labile blood products were systematically used in the treatment of bleeding. The average total dose of rFVIIa per patient was 10 ± 5 mg, i.e. an average total dose/weight of 129 ± 67 µg/kg. Postoperative thromboembolic events occurred in 22 patients (33%), in 73% of cases in the superior vena cava (head, neck and upper extremities).</p><p><strong>Conclusions: </strong>Our study allowed us to describe the use of rFVIIa in massive bleeding in cardiac surgery. The average total dose of rFVIIa administered was higher in patients with thromboembolic events than in those who did not. A more robust study will be conducted to investigate the attributability of rFVIIa to the occurrence of postoperative thromboembolic events.</p>","PeriodicalId":521031,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145277060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care.","authors":"Florence Ranchon, Florian Slimano, Maha Ayyoub, Charlotte Bérard, Anaïs Grand, Marie Kroemer, Xavier Paoletti, Vérane Schwiertz, Pascale Tomasini, Christophe Bardin, Emmanuel Raffoux, Catherine Rioufol, Régine Chevrier, Bertrand Pourroy, Jean-Louis Cazin","doi":"10.1016/j.pharma.2025.10.001","DOIUrl":"https://doi.org/10.1016/j.pharma.2025.10.001","url":null,"abstract":"<p><p>Hospital oncology pharmacy (HOP) is evolving in tandem with the rapid pace of oncology research, encompassing breakthroughs in anticancer therapies, the management of treatment-related toxicities, and the application of novel methodologies for evaluating therapeutic strategies. This paper presents a synthesis on these topics, based in part, on the latest scientific event organized by the French Society for Oncology Pharmacy (SFPO), known as St. Louis' Day. During this event, seven leading experts-comprising medical oncologists and HOPs-engaged in in-depth discussions on three pivotal themes: the assessment of therapeutic innovations, recent progress in cancer-related vaccinology, and the management of immune-related adverse events. The proceedings underscore the critical role of HOPs as key members of the interdisciplinary oncology team, driving ongoing advancements in the quality and safety of cancer care.</p>","PeriodicalId":521031,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145277107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cilianthaxone, a novel compound isolated from ethanolic extract of Ephedra ciliata and exploring its anti-inflammatory potential through in vitro, in vivo, and in silico studies.","authors":"Malik Saadullah, Abid Mahmood, M Fakhar-E-Alam, Asad Ali, Rubab Saher, Muhammad Asif","doi":"10.1016/j.pharma.2025.09.005","DOIUrl":"10.1016/j.pharma.2025.09.005","url":null,"abstract":"<p><p>The current study was designed to determine the anti-inflammatory potential of a novel compound isolated from ethanolic extract of Ephedra ciliata (ECE). The extract was fractionated and purified using various chromatographic techniques, followed by structural elucidation via spectroscopic methods. ECE and isolated compound cilianthaxone (ECE-2e-4) were analysed for acute toxicity by in vivo study for 14days and it was found that a dose of 2000mg/kg has no significant changes on animal body normal parameters. In vivo, animal studies like a hot plate and acetic acid-induced writhing methods were applied to determine the analgesic potential of both the ECE and cilianthaxone. In the hot plate, carrageenan-induced paw edema model, the cilianthaxone exhibited greater anti-inflammatory potential at a dose of up to 10mg/kg compared to the standard drug indomethacin. Cilianthaxone exhibited 85.35% inhibition compared to indomethacin, which showed 77.61% inhibition. The analgesic activity of the isolated compound was also confirmed by the acetic acid-indsuced writhing method, where cilianthaxone exhibited a delayed latency time of 30.50min, comparable to the standard drug morphine. Antioxidant properties of cilianthaxone were also confirmed through DPPH and NO scavenging methods and have IC₅₀ values of 14.28±0.43μg/kg and 15.60±0.21μg/kg, respectively. The chorioallantoic membrane (CAM) assay was also performed to check anti-angiogenesis, and no angio-toxicity was found. Furthermore, in silico studies were also performed to determine the binding mode and protein targeting ability of isolated compound. Overall, the current research highlights the significant anti-inflammatory effects and wound-healing potential of cilianthaxone, supported by its favorable target protein interactions.</p>","PeriodicalId":521031,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-Vivo and In-Silico analysis of Ficus carica-based acetone extract against the DEN-induced hepatocellular carcinoma.","authors":"Kiren Mustafa, Tang Qi, Sania Zaib, Hassan Khan Nasir, Karishma Marwat, Yuanda Song, Zhihe Li","doi":"10.1016/j.pharma.2025.09.004","DOIUrl":"10.1016/j.pharma.2025.09.004","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is one of the most fatal cancers responsible for mortality worldwide. For the first time, a randomized controlled study was conducted on 32 Balb c albino mice to evaluate the anticancer potential of the acetone-based extract of F. carica variety from Shandong province of China. Diethylamine nitrosamine (DEN) and carbon tetrachloride (CCl₄) were used as inducers of hepatic carcinoma in mice. We conducted an in vivo study on F. carica-based acetone (FA) extract that has already been proven effective against hepatoblastoma cancer (HepG2) cell lines in our previous experiments. The FA extract (60mg/kg) significantly attenuated serum levels of liver functional biomarkers (BUN, ALT, AST, ALP) and alpha-fetoprotein (AFP) in mice. Histopathological analysis revealed that the extract promoted liver tissue regeneration, restoring near-normal hepatic architecture after 60 days of treatment. Silymarin (50mg/kg), used as a positive control, similarly reduced liver injury biomarkers. Notably, the extract demonstrated comparable efficacy to silymarin, with significant reductions in serum BUN and AST levels. Complementing our in vivo results, in silico molecular docking and ADMET profiling revealed FA-derived phytochemicals (e.g., sitosterol, quercetin, luteolin) with efficacy rivaling or exceeding silymarin. These compounds exhibited strong binding affinities to hepatocellular carcinoma targets such as EGFR, VEGFR, and MMPs, thus suggesting multi-target therapeutic potential. The findings suggest that sitosterol, quercetin, and luteolin show competitive binding and favorable ADMET properties, proposing them as candidates for further experimental validation. This novel extract and its isolated compounds may represent a more effective and cost-efficient alternative to conventional hepatoprotective drugs for future therapeutic applications.</p>","PeriodicalId":521031,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of metabolic syndrome on health-related quality of life and its determinants in post-myocardial infarction patients.","authors":"Anam Anwar Sheikh, Tejashree Padmanabha Hola, Treesa P Varghese","doi":"10.1016/j.pharma.2025.09.003","DOIUrl":"10.1016/j.pharma.2025.09.003","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular diseases are the leading cause of morbidity and mortality worldwide. Health-related quality of life (HRQoL) is a key patient-reported outcome, especially in chronic conditions like myocardial infarction (MI). This study aimed to assess HRQoL and its determinants in post-MI patients with and without metabolic syndrome (MetS) using the EQ-5D-5L questionnaire.</p><p><strong>Methodology: </strong>A cross-sectional observational study was conducted among 160 inpatients (aged 25-75years) with MI in a tertiary care hospital. Patients who were on mechanical ventilation, or those with psychiatric disorders, or cognitive impairment were excluded. MetS was diagnosed using the revised NCEP-ATP III criteria, and the QoL was assessed using EQ-5D-5L questionnaire.</p><p><strong>Results: </strong>Of the 160 participants, 66.3% were male. The mean age was 58.54±10.02years. The mean EQ-5D-5L index was 0.70±0.26, and the EQ-VAS score was 66.09±15.59. MetS was observed with 75.6% of the population; women were more likely to have it (79.6%) than men (73.6%). Descriptive analysis showed that the women reported lower QoL than men, irrespective of their MetS status. The study result shows that, highest EQ-VAS score was observed in men with MetS (70.06±14.63), while women without MetS had the lowest EQ-5D Index (0.580±0.250). However, gender, MetS, and their interaction were not significant predictors of HRQoL, while occupation was the only significant determinant in this study.</p><p><strong>Conclusion: </strong>The occurrence of MetS in post-MI patients was very common, especially in women and those with concomitant conditions. Even if there are no significant impacts of gender or MetS on QoL after adjustment, MI recovery can be maximised through early detection and integrated risk management, which includes lifestyle changes and customised cardiac rehabilitation.</p>","PeriodicalId":521031,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Competency framework for patients with surgical jejunostomy: From theory to educational practice.","authors":"Cécile Auriault, Jean-François Huon, Marie De Montrichard, Adam Jirka, Marine Vidal, Soisic Lecomte, Nicolas Regenet, Pierre Nizet, Fabien Nativel","doi":"10.1016/j.pharma.2025.09.002","DOIUrl":"10.1016/j.pharma.2025.09.002","url":null,"abstract":"<p><strong>Objectives: </strong>Patients with a jejunostomy use their tube daily in most cases, which exposes them to various complications. However, to our knowledge, the current literature is limited regarding available educational interventions or tools for these patients, and no specific competency framework for surgical jejunostomy has been developed yet. This project aimed to develop a unique and adapted competency framework for surgical jejunostomy patients through a multiprofessional and consensus-driven approach and to create a fun educational tool based on this framework to promote an effective educational approach.</p><p><strong>Methods: </strong>A multidisciplinary working group was formed to develop the competency framework for patients with a surgical jejunostomy. Based on the identified priority competencies, an educational game was designed.</p><p><strong>Results: </strong>Fifty-nine competencies were identified to constitute the competency framework: twenty-eight related to knowledge, sixteen related to know-how and fifteen related to attitudes, each divided into six items. Among these, twenty competencies were considered as priorities. The \"Jejunostomy Game\", an educational tool inspired by Trivial Pursuit® was developed for patients using a surgical jejunostomy tube for feeding.</p><p><strong>Conclusion: </strong>This work appears essential to benefit both the patients and the various healthcare professionals who support them. It would be relevant to test the \"Jejunostomy Game\" to evaluate its effectiveness by measuring the knowledge and skills of patients.</p>","PeriodicalId":521031,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}